The Cooper Cos.

Rank: 41

2016 Rank49 Employees10,600 Revenue:$1,966,814,000 R&D Spend:$65,411,000 Fiscal year ending:10-31-16 Click here to see all 100

The Cooper Companies is a public holding company. Cooper operates through two business units, CooperVision (CVI) and CooperSurgical (CSI). CooperVision brings a perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women’s health clinicians with products and treatment options to improve the delivery of health care to women.

The Cooper Companies Acquires Assets of Recombine. The Cooper Companies' Women's Health Care Unit Acquires Genesis Genetics. The Cooper Companies' Women's Health Care Unit Acquires Research Instruments. The Cooper Companies' Women's Health Care Unit Acquires Reprogenetics. The Cooper Companies' Women's Healthcare Unit Acquires EndoSee. The Cooper Companies Completes Acquisition of Sauflon Pharmaceuticals and Announces $700 Million 3-Year Term Loan. The Cooper Companies Announces Definitive Agreements to Acquire Sauflon Pharmaceuticals Ltd.

Key Personnel: Robert Weiss, president & CEO; Daniel McBride, EVP, COO & president; Carol Kaufman, EVP, secretary, chief administrative officer & chief governance officer; Albert White III, EVP, CFO & chief strategy officer; Paul Remmell, president & CEO, CooperSurgical;

http://www.coopercos.com